Sarepta stock touches 52-week low at $99.46 amid market challenges

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock has faced a significant downturn, touching a 52-week low of $99.46. The biopharmaceutical company, known for its focus on the discovery and development of precision genetic medicines, has seen its shares struggle in a challenging market environment. InvestingPro data shows the company maintains strong fundamentals with a current ratio of 4.2 and impressive revenue growth of 53% in the last twelve months. Over the past year, Sarepta’s stock has experienced a notable decline, with a 1-year change showing a decrease of -18.08%. Investors are closely monitoring the company’s performance and potential catalysts that may influence its stock price in the coming months. Analyst targets suggest significant upside potential, with a high target of $215. InvestingPro subscribers can access 12 additional key insights and a comprehensive Pro Research Report, offering deeper analysis of Sarepta’s market position and growth prospects.

In other recent news, Sarepta Therapeutics reported strong financial results for the fourth quarter of 2024, with earnings per share (EPS) of $1.9, exceeding Wall Street’s forecast of $1.54. The company’s revenue for the quarter reached $658.4 million, surpassing the anticipated $589.45 million. Mizuho (NYSE:MFG) Securities noted that Sarepta’s fourth-quarter product revenues of $638.2 million exceeded both their estimate and the consensus estimate, maintaining an Outperform rating while slightly reducing the price target to $190. Additionally, Sarepta’s guidance for 2025 projects net product revenue between $2.9 billion and $3.1 billion, indicating a potential 70% increase.

Cantor Fitzgerald maintained its Overweight rating on Sarepta, with a price target of $163, adjusting revenue and operating expense estimates in line with the company’s guidance. Meanwhile, RBC Capital Markets also reaffirmed an Outperform rating for Sarepta, although it slightly lowered the price target to $161. Analysts at RBC Capital highlighted the possibility for Sarepta to exceed the $2.18 billion sales forecast for Elevidys, a key product for the company.

Scotiabank (TSX:BNS) initiated coverage on Sarepta with a Sector Perform rating and a price target of $105, acknowledging the success of Sarepta’s gene therapy product Elevidys. However, they expressed caution about potential risks, including competition in the Duchenne muscular dystrophy (DMD) gene therapy space. These developments provide investors with a comprehensive view of Sarepta Therapeutics’ recent performance and the varied perspectives of financial analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.